SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Winblad Bengt)) srt2:(2020-2024)
 

Search: (WFRF:(Winblad Bengt)) srt2:(2020-2024) > (2020) > Quantifying and Des...

Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions

Wimo, Anders (author)
Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning, Gävleborg,Karolinska Inst, Care Sci & Soc, Div Neurogeriatr, Dept Neurobiol, Stockholm, Sweden.;
Handels, Ron (author)
Karolinska Institutet
Winblad, Bengt (author)
Karolinska Institutet
show more...
Black, Christopher M. (author)
Merck & Co Inc, Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA.
Johansson, Gunilla (author)
Karolinska Institutet
Salomonsson, Stina (author)
Merck Sharp & Dohme Ltd, Ctr Observat & Real World Evidence CORE, Stockholm, Sweden.
Eriksdotter, Maria (author)
Karolinska Institutet
Khandker, Rezaul K. (author)
Merck & Co Inc, Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA.
show less...
 (creator_code:org_t)
IOS PRESS, 2020
2020
English.
In: Journal of Alzheimer's Disease. - : IOS PRESS. - 1387-2877 .- 1875-8908. ; 75:3, s. 891-902
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: A long-term horizon is necessary when the socioeconomic consequences and the potential effects of interventions in Alzheimer's disease (AD) are estimated. Objectives: To illustrate the potential societal costs of AD across the disease continuum and to illustrate the potential cost-effectiveness of a hypothetical intervention with disease modifying treatment (DMT). Methods: Based on the Swedish dementia registry, a Markov model was used to simulate a virtual cohort of 100,000 people with mild cognitive impairment (MCI) due to AD (AD-MCI) in Sweden for 40 years starting at the age of 60. A simulated hypothetical intervention assumed a 25% reduction in progression rate during AD-MCI and mild AD-dementia. A comprehensive set of sensitivity analyses was included. Results: The cumulative risk to develop dementia was 96%. The mean simulated survival was 19.0 years. The net present value for a person year with dementia was 252,843 SEK (about 29,500 US$). The cost effectiveness model illustrated how the hypothetical scenario of a 25% reduction in progression to AD-dementia would require 41 AD-MCI patients to be treated to prevent one case of AD-dementia (2,447 avoided AD-dementia cases of 100,000 with AD-MCI). Most scenarios illustrated hypothetical cost effectiveness (based on a willingness to pay level of 600,000 SEK (70,000 US$) per gained QALY), but not cost savings. Discussion: Lifetime societal costs of AD are substantial. A future DMT may be potentially cost-effective given assumed treatment effects and costs, but cost savings are unlikely.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

Alzheimer's disease
cost analysis
cost effectiveness
costs
dementia
disease-modifying treatment
economics

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view